or Try an Advanced Search...

    Technical Analysis for NLSP - NLS Pharmaceutics Ltd.

    Grade Last Price % Change Price Change
    F 3.43 1.93% 0.07
    NLSP closed up 1.93 percent on Friday, November 22, 2024, on 24 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical NLSP trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Inside Day Range Contraction 1.93%
    Wide Bands Range Expansion 1.93%
    Oversold Stochastic Weakness 1.93%
    Stochastic Buy Signal Bullish 4.26%
    Wide Bands Range Expansion 4.26%
    Older End-of-Day Signals for NLSP ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 16 hours ago
    Gap Up Closed about 17 hours ago
    Down 1% about 17 hours ago
    10 DMA Resistance about 17 hours ago
    Reversed from Up about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NLSP Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Attention Deficit Hyperactivity Disorder Drug Therapies Sleep Disorders Narcolepsy Amphetamine Methylphenidate Adhd Cataplexy Idiopathic Hypersomnia

    Is NLSP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
    Nov 5 NLS and Kadimastem stocks soar following merger agreement
    Nov 5 NLS Pharmaceutics, Kadimastem enter definitive merger agreement
    Nov 4 NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem
    Nov 4 NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
    Oct 28 NLS Pharmaceutics regains compliance with Nasdaq
    Oct 28 NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
    Oct 21 NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
    Oct 15 NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
    Sep 25 NLS Pharmaceutics to conduct reverse share split
    See more NLSP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.08
    52 Week Low 3.0
    Average Volume 268,516
    200-Day Moving Average 7.27
    50-Day Moving Average 4.51
    20-Day Moving Average 3.71
    10-Day Moving Average 3.43
    Average True Range 0.45
    RSI (14) 39.39
    ADX 19.79
    +DI 18.41
    -DI 19.90
    Chandelier Exit (Long, 3 ATRs) 3.40
    Chandelier Exit (Short, 3 ATRs) 4.34
    Upper Bollinger Bands 4.47
    Lower Bollinger Band 2.96
    Percent B (%b) 0.31
    BandWidth 40.56
    MACD Line -0.37
    MACD Signal Line -0.38
    MACD Histogram 0.0051
    Fundamentals Value
    Market Cap 122.35 Million
    Num Shares 35.7 Million
    EPS -0.50
    Price-to-Earnings (P/E) Ratio -6.86
    Price-to-Sales 0.00
    Price-to-Book 4.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.92
    Resistance 3 (R3) 3.94 3.79 3.84
    Resistance 2 (R2) 3.79 3.67 3.78 3.81
    Resistance 1 (R1) 3.61 3.59 3.54 3.59 3.78
    Pivot Point 3.47 3.47 3.43 3.46 3.47
    Support 1 (S1) 3.29 3.34 3.22 3.27 3.08
    Support 2 (S2) 3.14 3.27 3.13 3.05
    Support 3 (S3) 2.96 3.14 3.02
    Support 4 (S4) 2.94